RU98113711A - A NEW METHOD FOR TREATING RESISTANCE TO INSULIN - Google Patents
A NEW METHOD FOR TREATING RESISTANCE TO INSULINInfo
- Publication number
- RU98113711A RU98113711A RU98113711/14A RU98113711A RU98113711A RU 98113711 A RU98113711 A RU 98113711A RU 98113711/14 A RU98113711/14 A RU 98113711/14A RU 98113711 A RU98113711 A RU 98113711A RU 98113711 A RU98113711 A RU 98113711A
- Authority
- RU
- Russia
- Prior art keywords
- preceding paragraphs
- use according
- compound
- range
- denotes
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
- 102000004877 Insulin Human genes 0.000 title 1
- 108090001061 Insulin Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 206010022489 Insulin resistance Diseases 0.000 claims 4
- 210000004369 Blood Anatomy 0.000 claims 3
- 102000033175 CALCA Human genes 0.000 claims 3
- 101700017623 CALCA Proteins 0.000 claims 3
- 101700041770 CALCR Proteins 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 101710023382 S100A12 Proteins 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- RXWDEUWOJGGNHU-HXUWFJFHSA-N (3R)-1-[3-(5,6-dihydrodibenzo[1,2-a:1',2'-e][7]annulen-11-ylidene)propyl]piperidine-3-carboxylic acid Chemical compound C1[C@H](C(=O)O)CCCN1CCC=C1C2=CC=CC=C2CCC2=CC=CC=C21 RXWDEUWOJGGNHU-HXUWFJFHSA-N 0.000 claims 2
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004429 atoms Chemical group 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Claims (25)
где R1 и R2 независимо обозначают водород, галоген, трифторметил, C1-6-алкил или C1-6-алкокси; Y обозначает где только подчеркнутый атом принимает участие в циклической системе; X обозначает -O-, -S-, -CR7R8-, -CH2CH2-, - CH=CH=CH2-, -CH2-CH=CH- -CH2CH2CH2-, - CH= CH-, -NR9(C= O)-, -O-CH2-, -(C=O)-, или -(S=O)-, где R7, R8, и R9 независимо обозначают водород или C1-6-алкил; r обозначает 1, 2 или 3; m обозначает 1 или 2 и n обозначает 1, когда m равно 1; и n обозначает 0, когда m равно 2; R4 и R5 каждый, представляют водород или, когда m равно 2, могут вместе представлять связь; и R6 обозначает OH или C1-8-алкокси; или его фармацевтически приемлемой соли для производства фармацевтической композиции для снижения содержания глюкозы в крови и/или ингибирования активности CGRP.1. Application of the invention of general formula I
where R 1 and R 2 independently represent hydrogen, halogen, trifluoromethyl, C 1-6 -alkyl or C 1-6 -alkoxy; Y stands for where only the underlined atom takes part in the cyclic system; X is —O—, —S—, —CR 7 R 8 -, —CH 2 CH 2 -, —CH = CH = CH 2 -, —CH 2 —CH = CH— —CH 2 CH 2 CH 2 -, - CH = CH-, -NR 9 (C = O) -, -O-CH 2 -, - (C = O) -, or - (S = O) -, where R 7 , R 8 , and R 9 independently represent hydrogen or C 1-6 alkyl; r is 1, 2 or 3; m is 1 or 2 and n is 1 when m is 1; and n is 0 when m is 2; R 4 and R 5 each represent hydrogen or, when m is 2, may together represent a bond; and R 6 is OH or C 1-8 alkoxy; or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for reducing blood glucose and / or inhibiting CGRP activity.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK1426/95 | 1995-12-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU98113711A true RU98113711A (en) | 2000-06-20 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0236684B1 (en) | Galanthamine or analogues thereof for treating alzheimer's disease | |
RU2008133654A (en) | METHOD AND MEDICINE FOR TREATMENT OF SEVERE HEART FAILURE | |
RU2000131183A (en) | OXYMINO-ALKANIC ACID DERIVATIVES | |
JPH06122668A (en) | Tramadol n-oxide material, its enantiomer and composition and its use | |
BG64972B1 (en) | Agents with antidepressive effect | |
US20130296413A1 (en) | N-desmethyl-doxepin and methods of using the same to treat sleep disorders | |
EP1356812B1 (en) | Medicines for treatment and prevention of neurogenic pain | |
JP5624037B2 (en) | Compounds for the treatment of peripheral neuropathy | |
PT92799B (en) | Use of a partial glycine agonist B, in particular an amino-isoxazole derivative compound for the preparation of a medicament as an antipsychotic and a method for the preparation of a pharmaceutical composition comprising the said agonist | |
JP3007992B2 (en) | Inhibition of smooth muscle cell migration by (R) -amlodipine | |
EP0694299B1 (en) | The use of( a) bicycloheptane derivative(s) | |
RU98113711A (en) | A NEW METHOD FOR TREATING RESISTANCE TO INSULIN | |
JPH04504859A (en) | Extended-release (tight-binding) dopamine, serotonin or norepinephrine reuptake inhibitors as cocaine, amphetamine and phencyclidine antagonists | |
US6221858B1 (en) | Pyridyl-and pyrimidyl-piperazines in the treatment of substance abuse disorders | |
US7074961B2 (en) | Antidepressants and their analogues as long-acting local anesthetics and analgesics | |
AU706794B2 (en) | A novel combination of a beta-receptor blocker and an opioid | |
RU2001121195A (en) | ((Aminoiminomethyl) amino) alkanecarboxidamides and their use in therapy | |
AU619310B2 (en) | Lactamimides as calcium antagonists | |
NZ225426A (en) | Anti-arrhythmic pharmaceutical compositions, in unit dosage form, containing 4-amino-6,7-dimethoxy-2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinol-2-yl)quinoline | |
EP0450232B1 (en) | P-Guanidino benzoic acid derivatives for treatment of cerebrovascular contraction | |
JPS5989626A (en) | Asthma prevention or treatment | |
RU97113692A (en) | APPLICATION OF 3,4-DIPHENYLCHROMANES FOR OBTAINING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CEREBRAL DEGENERATIVE DISORDERS | |
Gallant | Antidepressant overdose: symptoms and treatment | |
JPH0311022A (en) | Drug composition | |
JPH07103032B2 (en) | Pharmaceutical composition containing N'-substituted N-phenylsulfonylurea for treating hypertension in insulin resistant subjects |